Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?
Rupp
Heinz
H
Rupp
Thomas P
TP
Maisch
Bernhard
B
D000818:Animals; D002334:Carnitine O-Palmitoyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004852:Epoxy Compounds / Q000627:therapeutic use; D005227:Fatty Acids / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects*; D005998:Glycine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D010084:Oxidation-Reduction; D047493:PPAR alpha / Q000378:metabolism*
D004791:Enzyme Inhibitors; D004852:Epoxy Compounds; D005227:Fatty Acids; D007004:Hypoglycemic Agents; D047493:PPAR alpha; C023010:4-hydroxyphenylglycine; D002334:Carnitine O-Palmitoyltransferase; C054207:etomoxir; D005998:Glycine